EU project on intelligent materials to regenerate bone tissue

More than half a million Europeans suffer from disorders in or serious defects of some part of their bone structure. So, graft or implant operations needed to repair the damage depend decisively on the materials used. The Nanobiocom project, funded under the EU's Sixth Framework Programme (FP6), is working on the regeneration and repair of bone tissue. Its aim is to come up with a substitute for bone tissue that can repair the bone and regenerate it in such a way that it will be able to carry out similar functions to those in its natural state.

In the case of significant deterioration of the bone, it may be necessary for the implant to provide both functional and physiological properties of the damaged item. In such circumstances, the bone implants have to comply with certain requisites capable of contributing to a reconstruction of the deteriorated bone tissue in the most efficient and least harmful way possible, without any serious repercussions. Another requirement involves the carrying out of the mechanical functions of the damaged bone while the desired regeneration takes place.

In addition, the solutions have to be capable of remedying particularly serious damage, such as those due to congenital deficiencies, degenerative illnesses, cancerous disorders and other damage caused by accidents. The implants required for this type of solutions are more complex and sophisticated than the small implants known until now.

So the Nanobiocom project will seek to develop a support (scaffold) made out of a compound material that is 'intelligent', proactive, and capable of repairing and regenerating bone tissue. For this purpose, it has to be bioactive, capable of acting on the tissue-generating system and its corresponding genes, as well as responding correctly to the physiological and biological changes, both internal and external, of that system.

It is also necessary for its size and shape characteristics, as well as its mechanical functions, to correspond with those of healthy bones.

The specific tasks of the three-year project are now on fine tuning the intelligent material, based on nanoparticles and of a biodegradable nature. Also in the pipeline is the development of the cell culture in three dimensions, as well as ensuring the biocompatibility of the material.

Ultimately, the scientists involved in the frontier research project hope it will open new doors in the development of nanobiotechnology.

For more information, please visit:
http://nanobiocom.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...